Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Sep
26
Today In Oncology
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
Robert Kyle Myeloma Expert Dies at 98
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo